Review on Mucormycosis: Pathogenesis, Epidemiology, Microbiology and Diagnosis


Cite item

Full Text

Abstract

Mucormycosis is a serious and invasive fungal infection caused by Mucorales fungi. This review article provides a concise overview of the pathogenesis, epidemiology, microbiology, and diagnosis of mucormycosis. The introduction section highlights the key microbiological properties of the pathogen and delves into the underlying mechanisms of mucormycosis pathogenesis, including the invasion and proliferation of the fungus within the host. The description of the disease section focuses on the epidemiology of mucormycosis, including its incidence, risk factors, and geographical distribution. It also explores the specific context of mucormycosis infection about COVID-19 and diabetes mellitus, highlighting the increased susceptibility observed in individuals with these conditions. A case study illustrates the clinical manifestations and challenges associated with mucormycosis, emphasizing the importance of early detection. Additionally, the review discusses the diagnosis of mucormycosis, emphasizing the significance of clinical assessment, radiological imaging, and microbiological tests for accurate and timely detection of the infection.

:Regarding treatment, the article covers the various therapeutic approaches, including antifungal therapy, surgical interventions, and management of underlying predisposing conditions. The limitations and challenges associated with treatment options are also addressed. This review aims to provide a comprehensive understanding of mucormycosis, equipping healthcare professionals with valuable insights into its pathogenesis, epidemiology, microbiology, and diagnostic strategies. By enhancing knowledge and awareness of this fungal infection, this review can improve patient outcomes through early diagnosis and appropriate management.

About the authors

Aditya Sharma

Department of Pharmacy, School of Medical and Allied Sciences, Galgotias University

Email: info@benthamscience.net

Md Alam

Department of Pharmacy, School of Medical and Allied Sciences, Galgotias University

Author for correspondence.
Email: info@benthamscience.net

Shivang Dhoundiyal

Department of Pharmacy, School of Medical and Allied Sciences, Galgotias University

Email: info@benthamscience.net

Pramod Sharma

Department of Pharmacy, School of Medical and Allied Sciences, Galgotias University

Email: info@benthamscience.net

References

  1. Dam P, Cardoso MH, Mandal S, et al. Surge of mucormycosis during the COVID-19 pandemic. Travel Med Infect Dis 2023; 52: 102557. doi: 10.1016/j.tmaid.2023.102557 PMID: 36805033
  2. Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: A systematic review and meta-analysis. J Infect 2020; 81(2): 266-75. doi: 10.1016/j.jinf.2020.05.046 PMID: 32473235
  3. Stone N, Gupta N, Schwartz I. Mucormycosis: Time to address this deadly fungal infection. Lancet Microbe 2021; 2(8): e343-4. doi: 10.1016/S2666-5247(21)00148-8 PMID: 35544192
  4. Rawson TM, Wilson RC, Holmes A. Understanding the role of bacterial and fungal infection in COVID-19. Clin Microbiol Infect 2021; 27(1): 9-11. doi: 10.1016/j.cmi.2020.09.025 PMID: 32979569
  5. Özbek L, Topçu U, Manay M, et al. COVID-19–associated mucormycosis: A systematic review and meta-analysis of 958 cases. Clin Microbiol Infect 2023; 29(6): 722-31. doi: 10.1016/j.cmi.2023.03.008 PMID: 36921716
  6. Saadi MHG, Hosseini SA, Khodamoradi Z, Mokhtaryan M, Omidifar N, Moghadami M. Comparison of mucormycosis infection between patients with and without a history of COVID-19 infection: A retrospective cohort study. Trans R Soc Trop Med Hyg 2023; 117(3): 174-8. doi: 10.1093/trstmh/trac078 PMID: 36001888
  7. COVID-19 weekly epidemiological update, 18 May 2021. Geneva: World Health Organization.. 2021.
  8. Ahmadikia K, Hashemi SJ, Khodavaisy S, et al. The double‐edged sword of systemic corticosteroid therapy in viral pneumonia: A case report and comparative review of influenza‐associated mucormycosis versus COVID‐19 associated mucormycosis. Mycoses 2021; 64(8): 798-808. doi: 10.1111/myc.13256 PMID: 33590551
  9. Garg D, Muthu V, Sehgal IS, et al. Coronavirus disease (Covid-19) associated mucormycosis (CAM): Case report and systematic review of literature. Mycopathologia 2021; 186(2): 289-98. doi: 10.1007/s11046-021-00528-2 PMID: 33544266
  10. Ranjbar K, Moghadami M, Mirahmadizadeh A, et al. Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: A triple-blinded randomized controlled trial. BMC Infect Dis 2021; 21(1): 337. doi: 10.1186/s12879-021-06045-3 PMID: 33838657
  11. Morales-Franco B, Nava-Villalba M, Medina-Guerrero EO, et al. Hostpathogen molecular factors contribute to the pathogenesis of Rhizopus spp. In diabetes mellitus. Curr Trop Med Rep 2021; 8(1): 6-17. doi: 10.1007/s40475-020-00222-1 PMID: 33500877
  12. Katragkou A, Walsh TJ, Roilides E. Why is mucormycosis more difficult to cure than more common mycoses? Clin Microbiol Infect 2014; 20 (Suppl. 6): 74-81. doi: 10.1111/1469-0691.12466 PMID: 24279587
  13. Grant P, Skilbeck CJ. Rhinocerebral mucormycosis: A devastating rhinological condition. Pract Diabetes 2014; 31(1): 37-9. doi: 10.1002/pdi.1826
  14. Richardson M. The ecology of the Zygomycetes and its impact on environmental exposure. Clin Microbiol Infect 2009; 15 (Suppl. 5): 2-9. doi: 10.1111/j.1469-0691.2009.02972.x PMID: 19754749
  15. Szebenyi C, Gu Y, Gebremariam T, et al. CotH genes are necessary for normal spore formation and virulence in mucor lusitanicus. MBio 2023; 14(1): e03386-22. doi: 10.1128/mbio.03386-22 PMID: 36625576
  16. Sullivan DJ, Moran GP, Coleman DC. Fungal Infections of Humans Fungi: Biology and Applications. Wiley 2011; pp. 257-78. doi: 10.1002/9781119976950.ch10
  17. Walther G, Wagner L, Kurzai O. Updates on the taxonomy of mucorales with an emphasis on clinically important taxa. J Fungi 2019; 5(4): 106. doi: 10.3390/jof5040106 PMID: 31739583
  18. Krüger W, Vielreicher S, Kapitan M, Jacobsen I, Niemiec M. Fungal-bacterial interactions in health and disease. Pathogens 2019; 8(2): 70. doi: 10.3390/pathogens8020070 PMID: 31117285
  19. Köhler JR, Casadevall A, Perfect J. The spectrum of fungi that infects humans. Cold Spring Harb Perspect Med 2015; 5(1): a019273. doi: 10.1101/cshperspect.a019273 PMID: 25367975
  20. Spellberg B. Vaccines for invasive fungal infections. F1000 Med Rep 2011; 3: 13. doi: 10.3410/M3-13 PMID: 21876719
  21. Shoham S, Levitz SM. The immune response to fungal infections. Br J Haematol 2005; 129(5): 569-82. doi: 10.1111/j.1365-2141.2005.05397.x PMID: 15916679
  22. Soliman SSM, Baldin C, Gu Y, et al. Mucoricin is a ricin-like toxin that is critical for the pathogenesis of mucormycosis. Nat Microbiol 2021; 6(3): 313-26. doi: 10.1038/s41564-020-00837-0 PMID: 33462434
  23. Olsson S, Bonfante P, Pawlowska TE. Ecology and evolution of fungal-bacterial interactions InThe Fungal Community Its Organization and Role in the Ecosystem. (4th ed.). CRC Press Taylor & Francis Group 2017; pp. 563-84.
  24. Reid G, Lynch JP III, Fishbein MC, Clark NM. Mucormycosis. Semin Respir Crit Care Med 2020; 41(1): 099-114. doi: 10.1055/s-0039-3401992 PMID: 32000287
  25. Song Y, Qiao J, Giovanni G, et al. Mucormycosis in renal transplant recipients: Review of 174 reported cases. BMC Infect Dis 2017; 17(1): 283. doi: 10.1186/s12879-017-2381-1 PMID: 28420334
  26. Chikley A, Ben-Ami R, Kontoyiannis DP. Mucormycosis of the central nervous system. J Fungi 2019; 5(3): 59. doi: 10.3390/jof5030059 PMID: 31288475
  27. Kashyap S, Bernstein J, Ghanchi H, Bowen I, Cortez V. Diagnosis of rhinocerebral mucormycosis by treatment of cavernous right internal carotid artery occlusion with mechanical thrombectomy: special case presentation and literature review. Front Neurol 2019; 10: 264. doi: 10.3389/fneur.2019.00264 PMID: 30972005
  28. Kawahara Y, Wada S, Nijima H, et al. Rhinocerebral mucormycosis with temporal artery thrombosis in an adolescent following hla-haploidentical stem cell transplantation. J Pediatr Hematol Oncol 2018; 40(7): e461-3. doi: 10.1097/MPH.0000000000001020 PMID: 29200154
  29. Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: A systematic review and meta-analysis. SSRN Electron J 2020. doi: 10.2139/ssrn.3594598
  30. Loh JT, Lam KP. Fungal infections: Immune defense, immunotherapies and vaccines. Adv Drug Deliv Rev 2023; 196: 114775. doi: 10.1016/j.addr.2023.114775 PMID: 36924530
  31. Song G, Liang G, Liu W. Fungal co-infections associated with global COVID-19 pandemic: A clinical and diagnostic perspective from China. Mycopathologia 2020; 185(4): 599-606. doi: 10.1007/s11046-020-00462-9 PMID: 32737747
  32. Suganya R, Malathi N, Karthikeyan V, Janagaraj VD. Mucormycosis: A brief review. J Pure Appl Microbiol 2019; 13(1): 161-5. doi: 10.22207/JPAM.13.1.16
  33. Jeong W, Keighley C, Wolfe R, et al. The epidemiology and clinical manifestations of mucormycosis: A systematic review and meta-analysis of case reports. Clin Microbiol Infect 2019; 25(1): 26-34. doi: 10.1016/j.cmi.2018.07.011 PMID: 30036666
  34. Cornely OA, Alastruey-Izquierdo A, Arenz D, et al. Global guideline for the diagnosis and management of mucormycosis: An initiative of the european confederation of medical mycology in cooperation with the mycoses study group education and research consortium. Lancet Infect Dis 2019; 19(12): e405-21. doi: 10.1016/S1473-3099(19)30312-3 PMID: 31699664
  35. Corzo-León DE, Chora-Hernández LD, Rodríguez-Zulueta AP, Walsh TJ. Diabetes mellitus as the major risk factor for mucormycosis in Mexico: Epidemiology, diagnosis, and outcomes of reported cases. Med Mycol 2018; 56(1): 29-43. doi: 10.1093/mmy/myx017 PMID: 28431008
  36. Mekonnen ZK, Ashraf DC, Jankowski T, et al. Acute invasive rhino-orbital mucormycosis in a patient with COVID-19-associated acute respiratory distress syndrome. Ophthal Plast Reconstr Surg 2021; 37(2): e40-80. doi: 10.1097/IOP.0000000000001889 PMID: 33229953
  37. Mehta S, Pandey A. Rhino-orbital mucormycosis associated with COVID 19. Cureus 2020; 12(9): e10726. doi: 10.7759/cureus.10726 PMID: 33145132
  38. Banerjee A, Das M, Verma P, et al. COVID-19 and mucormycosis of orofacial region: A scoping review. Cureus 2023; 15(4): e37984. doi: 10.7759/cureus.37984 PMID: 37223184
  39. Tahiri G, Lax C, Cánovas-Márquez JT, et al. Mucorales and mucormycosis: Recent insights and future prospects. J Fungi 2023; 9(3): 335. doi: 10.3390/jof9030335 PMID: 36983503
  40. Lamoth F. Novel approaches in the management of mucormycosis. Curr Fungal Infect Rep 2023; 17(2): 98-107. doi: 10.1007/s12281-023-00463-3 PMID: 37360854
  41. Harpf V, Rambach G, Parth N, et al. Complement, but not platelets, plays a pivotal role in the outcome of mucormycosis In vivo. J Fungi 2023; 9(2): 162. doi: 10.3390/jof9020162 PMID: 36836277
  42. Drogari-Apiranthitou M, Skiada A, Panayiotides I, et al. Epidemiology of mucormycosis in greece; results from a nationwide prospective survey and published case reports. J Fungi 2023; 9(4): 425. doi: 10.3390/jof9040425 PMID: 37108880
  43. Azhar A, Khan WH, Khan PA, Alhosaini K, Owais M, Ahmad A. Mucormycosis and COVID-19 pandemic: Clinical and diagnostic approach. J Infect Public Health 2022; 15(4): 466-79. doi: 10.1016/j.jiph.2022.02.007 PMID: 35216920
  44. Skiada A, Drogari-Apiranthitou M, Pavleas I, Daikou E, Petrikkos G. Global cutaneous mucormycosis: A systematic review. J Fungi 2022; 8(2): 194. doi: 10.3390/jof8020194 PMID: 35205948
  45. Dannaoui E. Recent developments in the diagnosis of mucormycosis. J Fungi 2022; 8(5): 457. doi: 10.3390/jof8050457 PMID: 35628713
  46. Smith C, Lee SC. Current treatments against mucormycosis and future directions. PLoS Pathog 2022; 18(10): e1010858. doi: 10.1371/journal.ppat.1010858 PMID: 36227854
  47. Alloush TK, Mansour O, Alloush AT, et al. Rhino-orbito-cerebral mucormycosis during the COVID-19 third wave in 2021: An Egyptian preliminary report from a single tertiary hospital. Neurol Sci 2022; 43(2): 799-809. doi: 10.1007/s10072-021-05740-y PMID: 34787754
  48. Veisi A, Bagheri A, Eshaghi M, Rikhtehgar MH, Rezaei Kanavi M, Farjad R. Rhino-orbital mucormycosis during steroid therapy in COVID-19 patients: A case report. Eur J Ophthalmol 2022; 32(4): NP11-6. doi: 10.1177/11206721211009450 PMID: 33843287
  49. Sharma A, Goel A. Mucormycosis: Risk factors, diagnosis, treatments, and challenges during COVID-19 pandemic. Folia Microbiol 2022; 67(3): 363-87. doi: 10.1007/s12223-021-00934-5 PMID: 35220559
  50. Niyazi D, Belcheva M, Vergiev S, Kaleva V, Stoeva T. A case of primary multifocal cutaneous mucormycosis in a pediatric patient with newly diagnosed acute lymphoblastic leukemia. Medicina 2023; 59(5): 905. doi: 10.3390/medicina59050905 PMID: 37241137
  51. Keerthika R, Narwal A, Kamboj M, et al. Mucor infection associated with global COVID-19 pandemic - an institutional histopathological study. Med Oral Patol Oral Cir Bucal 2023; 28(2): e99-e107. doi: 10.4317/medoral.25130 PMID: 36806020
  52. Hussain MK, Ahmed S, Khan A, Siddiqui AJ, Khatoon S, Jahan S. Mucormycosis: A hidden mystery of fungal infection, possible diagnosis, treatment and development of new therapeutic agents. Eur J Med Chem 2023; 246: 115010. doi: 10.1016/j.ejmech.2022.115010 PMID: 36566630
  53. Varaiya A, Sundaresan A. Emerging mucormycosis: Problems and treatments.In: Fungi and Fungal Products in Human Welfare and Biotechnology. Singapore: Springer Nature Singapore 2023; pp. 97-125.
  54. Mahler B, Parliteanu OA, Alexe O, et al. Mucormycosis in a patient with Severe COVID-19 Disease—The First Case Report in Romania and a Literature Review. Med 2023; 59(3): 555. doi: 10.3390/medicina59030555 PMID: 36984555
  55. Jacobsen ID. Mouse Models of Mucormycosis. Methods Mol Biol 2023; 2667: 181-96. doi: 10.1007/978-1-0716-3199-7_14
  56. Aasia Batool S, Kumari U, Surani S. Two rare diseases, one patient: A case report of mucormycosis and granulomatous polyangiitis. Case Rep Infect Dis 2023; 2023: 1-5. doi: 10.1155/2023/7934700 PMID: 37207042
  57. Reid G, Lynch JP III, Fishbein MC, Clark NM. Mucormycosis. Semin Respir Crit Care Med 2020; 41(1): 99-114. doi: 10.1055/s-0039-3401992 PMID: 32000287
  58. Singh AK, Singh R, Joshi SR, Misra A. Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India. Diabetes Metab Syndr 2021; 15(4): 102146. doi: 10.1016/j.dsx.2021.05.019 PMID: 34192610
  59. Prakash H, Chakrabarti A. Epidemiology of mucormycosis in India. Microorganisms 2021; 9(3): 523. doi: 10.3390/microorganisms9030523 PMID: 33806386
  60. Patel A, Agarwal R, Rudramurthy SM, et al. Multicenter epidemiologic study of coronavirus disease–associated mucormycosis, India. Emerg Infect Dis 2021; 27(9): 2349-59. doi: 10.3201/eid2709.210934 PMID: 34087089
  61. Werthman-Ehrenreich A. Mucormycosis with orbital compartment syndrome in a patient with COVID-19. Am J Emerg Med 2021; 42: 264.e5-8. doi: 10.1016/j.ajem.2020.09.032 PMID: 32972795
  62. Steinbrink JM, Miceli MH. Mucormycosis. Infect Dis Clin 2021; 35(2): 435-52. doi: 10.1016/j.idc.2021.03.009 PMID: 34016285
  63. Sharma S, Grover M, Bhargava S, Samdani S, Kataria T. Post coronavirus disease mucormycosis: A deadly addition to the pandemic spectrum. J Laryngol Otol 2021; 135(5): 442-7. doi: 10.1017/S0022215121000992 PMID: 33827722
  64. Maini A, Tomar G, Khanna D, Kini Y, Mehta H, Bhagyasree V. Sino-orbital mucormycosis in a COVID-19 patient: A case report. Int J Surg Case Rep 2021; 82: 105957. doi: 10.1016/j.ijscr.2021.105957 PMID: 33964720
  65. Agrawal GA, Ravani SA, Leuva P, Modi P, Amin K. Rise of the phoenix: Mucormycosis in COVID-19 times. Indian J Ophthalmol 2021; 69(6): 1563-8. doi: 10.4103/ijo.IJO_310_21 PMID: 34011742
  66. Eker C, Tarkan O, Surmelioglu O, et al. Alternating pattern of rhino-orbital–cerebral mucormycosis with COVID-19 in diabetic patients. Eur Arch Otorhinolaryngol 2023; 280(1): 219-26. doi: 10.1007/s00405-022-07526-0 PMID: 35768700
  67. Saldanha M, Reddy R, Vincent MJ. Title of the article: Paranasal mucormycosis in COVID-19 patient. Indian J Otolaryngol Head Neck Surg 2021; (Apr): 1-4. doi: 10.1007/s12070-021-02574-0 PMID: 33903850
  68. Khatri A, Chang KM, Berlinrut I, Wallach F. Mucormycosis after Coronavirus disease 2019 infection in a heart transplant recipient – Case report and review of literature. J Mycol Med 2021; 31(2): 101125. doi: 10.1016/j.mycmed.2021.101125 PMID: 33857916
  69. Buil JB, van Zanten ARH, Bentvelsen RG, et al. Case series of four secondary mucormycosis infections in COVID-19 patients, the Netherlands, December 2020 to May 2021. Euro Surveill 2021; 26(23): 2100510. doi: 10.2807/1560-7917.ES.2021.26.23.2100510 PMID: 34114540
  70. Rocha ICN, Hasan MM, Goyal S, et al. COVID‐19 and mucormycosis syndemic: Double health threat to a collapsing healthcare system in India. Trop Med Int Health 2021; 26(9): 1016-8. doi: 10.1111/tmi.13641 PMID: 34117677
  71. Mishra N, Mutya VSS, Thomas A, et al. A case series of invasive mucormycosis in patients with COVID-19 infection. Int J Otorhinolaryngol Head Neck Surg 2021; 7(5): 867-70. doi: 10.18203/issn.2454-5929.ijohns20211583
  72. Arana C, Cuevas Ramírez RE, Xipell M, et al. Mucormycosis associated with COVID‐19 in two kidney transplant patients. Transpl Infect Dis 2021; 23(4): e13652. doi: 10.1111/tid.13652 PMID: 34038014
  73. Nehara HR, Puri I, Singhal V, Ih S, Bishnoi BR, Sirohi P. Rhinocerebral mucormycosis in COVID-19 patient with diabetes a deadly trio: Case series from the north-western part of India. Indian J Med Microbiol 2021; 39(3): 380-3. doi: 10.1016/j.ijmmb.2021.05.009 PMID: 34052046
  74. Kumar M, Sarma DK, Shubham S, et al. Mucormycosis in COVID-19 pandemic: Risk factors and linkages. Curr Res Microb Sci 2021; 2: 100057. doi: 10.1016/j.crmicr.2021.100057 PMID: 34396355
  75. Prakash H, Chakrabarti A. Global epidemiology of mucormycosis. J Fungi 2019; 5(1): 26. doi: 10.3390/jof5010026 PMID: 30901907
  76. Samaddar A, Shrimali T, Sharma A. Mucormycosis caused by Apophysomyces species: An experience from a tertiary care hospital in Western India and systematic review of global cases. Mycoses 2023; 66(3): 181-95. doi: 10.1111/myc.13538 PMID: 36227645
  77. Muthu V, Agarwal R, Rudramurthy SM, et al. Multicenter case–control study of COVID-19–Associated mucormycosis outbreak, India. Emerg Infect Dis 2023; 29(1): 8-19. doi: 10.3201/eid2901.220926 PMID: 36573628
  78. Osman NA, Anwar MM, Singh B, Gupta GK, Rabie AM. A peek behind the curtain in the diagnosis and management of COVID-19-Associated Mucormycosis (CAM). J Egypt Public Health Assoc 2023; 98(1): 4. doi: 10.1186/s42506-022-00125-1 PMID: 36859556
  79. Bonifaz A, Tirado-Sánchez A, Araiza J, Hernández-Medel ML. Mucormycosis in the COVID-19 scenario beyond hospitalized patients. Future Microbiol 2023; 18(1): 5-8. doi: 10.2217/fmb-2022-0147 PMID: 36648217
  80. Gupta S, Goyal R, Kaore NM. Rhino-orbital-cerebral mucormycosis: Battle with the deadly enemy. Indian J Otolaryngol Head Neck Surg 2020; 72(1): 104-11. doi: 10.1007/s12070-019-01774-z PMID: 32158665
  81. Chauhan K, Soni D, Sarkar D, et al. Mucormycosis after COVID-19 in a patient with diabetes. Lancet 2021; 398(10301): e10. doi: 10.1016/S0140-6736(21)01641-X PMID: 34363754
  82. Li C, Gong Z, Pataer P, Shao B, Fang C. A retrospective analysis for the management of oromaxillofacial invasive mucormycosis and systematic literature review. BMC Oral Health 2023; 23(1): 115. doi: 10.1186/s12903-023-02823-4 PMID: 36810012
  83. Joshi AR, Muthe MM, Patankar SH, Athawale A, Achhapalia Y CT. and MRI findings of invasive mucormycosis in the setting of covid-19: experience from a single center in India. AJR Am J Roentgenol 2021; 217(6): 1431-2. doi: 10.2214/AJR.21.26205 PMID: 34161127
  84. SeyedAlinaghi S, Karimi A, Barzegary A, et al.. Retracted: Mucormycosis infection in patients with COVID ‐19: A systematic review. Health Sci Rep 2022; 5(2): e529. doi: 10.1002/hsr2.529 PMID: 35252593
  85. Klimko N, Khostelidi S, Shadrivova O, et al. Contrasts between mucormycosis and aspergillosis in oncohematological patients. Med Mycol 2019; 57 (Suppl. 2): S138-44. doi: 10.1093/mmy/myy116 PMID: 30816977
  86. Dulski TM, DeLong M, Garner K, et al. Notes from the Field: COVID-19–Associated Mucormycosis — Arkansas, July–September 2021. MMWR Morb Mortal Wkly Rep 2021; 70(50): 1750-1. doi: 10.15585/mmwr.mm7050a3 PMID: 34914674
  87. Martínez-Herrera E, Julián-Castrejón A, Frías-De-León MG, Moreno-Coutiño G. Rhinocerebral mucormycosis to the rise? The impact of the worldwide diabetes epidemic. An Bras Dermatol 2021; 96(2): 196-9. doi: 10.1016/j.abd.2020.06.008 PMID: 33531184
  88. Essar MY, Khan H, Babar MS, et al. Mucormycosis, conflicts and COVID‐19: A deadly recipe for the fragile health system of Afghanistan. Int J Health Plann Manage 2022; 37(1): 543-6. doi: 10.1002/hpm.3292 PMID: 34333804
  89. G Alshahawey M,. S El-Housseiny G, S Elsayed N, Y Alshahrani M, Wakeel LMEL, M Aboshanab K. New insights on mucormycosis and its association with the COVID-19 pandemic. Future Sci OA 2022; 8(2): FSO772. doi: 10.2144/fsoa-2021-0122 PMID: 35059222
  90. Alexander BD, Lamoth F, Heussel CP, et al. Guidance on imaging for invasive pulmonary aspergillosis and mucormycosis: From the imaging working group for the revision and update of the consensus definitions of fungal disease from the EORTC/MSGERC. Clin Infect Dis 2021; 72 (Suppl. 2): S79-88. doi: 10.1093/cid/ciaa1855 PMID: 33709131
  91. Chakrabarti A, Singh S. Management of Mucormycosis. Curr Fungal Infect Rep 2020; 14(4): 348-60. doi: 10.1007/s12281-020-00406-2
  92. Pal P, Chatterjee N, Ghosh S, et al. COVID associated mucormycosis: A study on the spectrum of clinical, biochemical and radiological findings in a series of ten patients. J Assoc Physicians India 2021; 69(10): 11-2. PMID: 34781648
  93. Bigot J, Godmer A, Prudenté L, et al. Diagnosis of mucormycosis using an intercalating dye-based quantitative PCR. Med Mycol 2022; 60(4): myac015. doi: 10.1093/mmy/myac015 PMID: 35188208
  94. Fuloria S, Fuloria N, Subramaniyan V, et al. COVID-19-associated mucormycosis and treatments. Asian Pac J Trop Med 2021; 14(9): 401. doi: 10.4103/1995-7645.326253

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bentham Science Publishers